Skip to content

Premature Infants Receiving Milking or Delayed Cord Clamping: PREMOD2

Premature Infants Receiving Milking or Delayed Cord Clamping: Randomized Controlled Multicenter Non-inferiority Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03019367
Acronym
PREMOD2
Enrollment
1201
Registered
2017-01-12
Start date
2017-06-06
Completion date
2022-09-16
Last updated
2022-11-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Death; Neonatal, Intraventricular Haemorrhage Neonatal

Keywords

Premature infants, Umbilical cord milking, Delayed cord clamping, Intraventricular Hemorrhage, Death

Brief summary

This study is being done to find out whether umbilical cord milking (UCM) is at least as good as or better than delayed cord clamping (DCC) to reduce bleeding in the brain or prevent death in premature newborns. The investigators will study short and long term outcomes of infants delivered before 32 weeks gestation that receive either UCM or DCC. \* The trial was stopped by the DSMB for safety in the small strata. They subsequently allowed for continuation of the trial in infants 29-32+6 wk GA.

Detailed description

Aim 1. Compare the incidence of severe intraventricular hemorrhage (IVH) and/or death in premature newborns \<33 weeks gestational age (GA) delivered by C/S receiving UCM to those receiving DCC. Hypothesis1: First demonstrate infants in the UCM group are not inferior to the DCC group (reject H10). Hypothesis2: If H1 is true, demonstrate lower incidence of severe IVH and/or death in UCM infants compared to DCC. Aim 2. Compare the safety and efficacy profiles of premature newborns \<33 weeks GA delivered by C/S receiving UCM vs. DCC during their hospitalization. Hypothesis3: UCM group will have a decreased need for resuscitation interventions with no differences in bilirubin or polycythemia compared to DCC. Hypothesis4: UCM group will have improved blood pressures in the first 24 hours of life compared to DCC. Aim 3 (exploratory). To compare the outcomes of premature newborns \<33 weeks GA delivered by C/S (Cesarean section) (from Aims 1 and 2) with those born by V/D (vaginal delivery) receiving UCM or DCC.

Interventions

PROCEDUREUmbilical cord milking UCM

At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before it is clamped. This procedure infuses a placental transfusion of blood into the preterm neonate and can be done in 15-20 seconds.

At delivery, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 60 seconds.

Sponsors

Sharp Mary Birch Hospital for Women & Newborns
CollaboratorOTHER
Loma Linda University
CollaboratorOTHER
University of Pittsburgh
CollaboratorOTHER
Providence Hospital
CollaboratorOTHER
University of Alabama at Birmingham
CollaboratorOTHER
University of Alberta
CollaboratorOTHER
University College Cork
CollaboratorOTHER
University of Ulm
CollaboratorOTHER
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH
Christiana Care Health Services
CollaboratorOTHER
Sharp Grossmont Hospital
CollaboratorOTHER
University of Utah
CollaboratorOTHER
University of Mississippi Medical Center
CollaboratorOTHER
PIH Health Good Samaritan Hospital
CollaboratorUNKNOWN
University of California, Irvine
CollaboratorOTHER
Children's Hospital Medical Center, Cincinnati
CollaboratorOTHER
Cook County Health
CollaboratorOTHER_GOV
St. Louis University
CollaboratorOTHER
LAC+USC Medical Center
CollaboratorOTHER
Sharp HealthCare
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Masking description

It is not possible to blind the delivering obstetrician, however all other caregivers will be blinded. The procedure will be documented as placental transfusion in the delivery summary or admission-progress notes and all study assessments whether primary (head US) or secondary (neurodevelopmental exams) will be performed by blinded team members.

Eligibility

Sex/Gender
ALL
Age
23 Weeks to 33 Weeks
Healthy volunteers
No

Inclusion criteria

* 23 to 32 +6 Gestational age (currently enrolling 29 to 32+6 weeks) * Multiples without Twin-to-twin Transfusion Syndrome (TTTS)

Exclusion criteria

* Congenital anomalies * Major cardiac defects * Placental abruption or previa with hemorrhage * Cord prolapse * Hydrops * Bleeding Accreta * Monochorionic multiples with evidence of TTTS * Fetal or maternal risk (i.e. compromise) * Parents declined study * Unlikely to return for 2 yr Follow Up

Design outcomes

Primary

MeasureTime frameDescription
Incidence of severe IVH or deathThrough study completion at death or discharge, up to 6 months corrected gestational age (CGA)Severe intraventricular hemorrhage of grade 3 or 4 or death

Secondary

MeasureTime frameDescription
Severe IVH (Grade 3 or 4)Through study completion at discharge, up to 6 months corrected gestational age (CGA)Severe intraventricular hemorrhage (bleeding in the brain parenchyma and/or ventricular dilation)
Hemoglobin/Hematocrit at 4 hours4 +/- 2 hours of lifehemoglobin/hematocrit
All Grade IVHThrough study completion at discharge, up to 6 months corrected gestational age (CGA)Any intraventricular hemorrhage (grades 1-4)
Delivery room interventionsIn the first 10 minutes of lifeResuscitation interventions including positive pressure ventilation, continuous positive airway pressure, intubation, chest compressions and medications
Blood pressures in the first 24 hours of lifeIn the first 24 hours of lifeBlood pressure on admission, 6, 12, 18 and 24 hours of life
Incidence of Severe IVH or death in infants <28 weeks gestationThrough study completion at discharge, up to 6 months corrected gestational age (CGA)Severe intraventricular hemorrhage (grade 3 or 4) in infants born under 28 weeks gestational age

Countries

Canada, Germany, Ireland, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026